Home  |  Contact

Cellosaurus LNCaP-EnzR (CVCL_RA57)

[Text version]

Cell line name LNCaP-EnzR
Accession CVCL_RA57
Resource Identification Initiative To cite this cell line use: LNCaP-EnzR (RRID:CVCL_RA57)
Comments Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; MDV-3100).
Omics: Transcriptome analysis.
Sequence variations Homozygous for AR p.Thr878Ala (c.2632A>G) (from parent cell line).
Heterozygous for MEN1 p.Tyr313Ter (c.939T>A) (from parent cell line).
Heterozygous for PIK3R1 p.Arg639Ter (c.1915C>T) (from parent cell line).
PTEN p.Lys6Argfs*4 (c.17_18delAA) (from parent cell line).
Disease Prostate carcinoma (NCIt: C4863)
Derived from metastatic site: Left supraclavicular lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0395 (LNCaP)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line
Publications

PubMed=27036029; DOI=10.18632/oncotarget.8456
Kregel S., Chen J.L., Tom W., Krishnan V., Kach J., Brechka H., Fessenden T.B., Isikbay M., Paner G.P., Szmulewitz R.Z., Vander Griend D.J.
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Oncotarget 7:26259-26274(2016)

Cross-references
Gene expression databases GEO; GSM2069526
GEO; GSM2069527
GEO; GSM2069528
GEO; GSM2069529
Other Wikidata; Q54902837
Entry history
Entry creation05-Mar-2018
Last entry update02-Jul-2020
Version number4